PH Deck logoPH Deck

Fill arrow
JabBuddy GLP-1 Shot Jab Tracker
Brown line arrowSee more Products
JabBuddy GLP-1 Shot Jab Tracker
Track GLP-1 injections, weight, water, site rotation
# Healthcare
Featured on : Nov 19. 2025
Featured on : Nov 19. 2025
What is JabBuddy GLP-1 Shot Jab Tracker?
Transform your GLP-1 journey with JabBuddy Perfect for managing Ozempic, Wegovy, Mounjaro, Zepbound, and compounded Semaglutide or Tirzepatide. - Enter log entry for today, or any past date - Log injections with site rotation - Log Weight in lb(US),kg(EU),st lb(UK) - Log Side Effects - Log Water - Import past data form CSV and export - Notifications for injections, re-orders, water reminders that you can turn off - Dark/light mode support - Achievements system
Problem
Users managing GLP-1 injections (e.g., Ozempic, Wegovy) rely on manual methods like spreadsheets or notes to track injections, weight, water intake, and side effects. Manual tracking is error-prone, lacks reminders, and complicates site rotation management.
Solution
A mobile app enabling users to log injections, track weight/water, set reminders, and export data. Core features include injection site rotation management, customizable notifications, and achievements (e.g., reminders for reordering medication).
Customers
Patients using GLP-1 medications (e.g., Ozempic, Mounjaro) for diabetes or obesity, aged 25–65, who need structured tracking for injections and health metrics.
Unique Features
Combines injection site rotation tracking, CSV data import/export, customizable reminders for water/reorders, and an achievements system to encourage adherence.
User Comments
Simplifies tracking GLP-1 routines
Helps avoid missed doses
Useful for monitoring side effects
Achievements keep users motivated
Dark/light mode appreciated
Traction
Newly launched on Product Hunt (1.2k+ upvotes), basic version live with plans to add glucose tracking and family sharing per founder comments.
Market Size
The global GLP-1 receptor agonist market was valued at $4.3 billion in 2022 (primarily diabetes/obesity drugs), with Novo Nordisk's Ozempic alone generating $12B annually in 2023.